|Bid||1.15 x 1800|
|Ask||0.00 x 1200|
|Day's Range||1.50 - 1.55|
|52 Week Range||1.35 - 3.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2018 - Mar 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.83|
Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that its 2018 Annual Meeting of Shareholders (the “Annual Meeting”), scheduled for Thursday, June 14, 2018, was convened and Proposals 1, 2 and 4, each as set forth in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 23, 2018 (the “Proxy Statement”), were approved. The Company adjourned the Annual Meeting with respect to Proposal 3, a proposal to amend its amended and restated certificate of incorporation to increase the number of authorized shares of common stock from 50,000,000 to 100,000,000 shares. While Proposal 3 has received the support of the majority of shares voting on the proposal, approval of more than 50% of all outstanding shares of Rexahn common stock as of April 18, 2018 is necessary for the proposal to be approved.
Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that preliminary data from a Phase 2a clinical trial of RX-5902 in metastatic triple negative breast cancer (TNBC) and updated data from the Phase 2a trial of RX-3117 in advanced bladder cancer were presented at the American Society of Clinical Oncology (ASCO) 2018 annual meeting on June 2, 2018. “We are encouraged by the data presented at ASCO including a complete response in advanced bladder cancer in a patient being treated with RX-3117.
Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical-stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, advances its ongoing Phase 2a study of RX-3117 in combination with Abraxane® in first-line patients with metastatic pancreatic cancer following a recently completed routine Safety Monitoring Committee (SMC) review. The SMC has confirmed that the combination of RX-3117 and Abraxane is safe and well tolerated and that the two drugs can be given in combination at the highest recommended doses for both agents which is once-daily oral administration of 700 mg RX-3117 five times per week plus once-weekly Abraxane® at 125 mg/m2 IV given on a three weeks on/one week off per four-week cycle schedule.
ROCKVILLE, Md., May 07, 2018-- Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced financial results ...
NEW YORK, May 03, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PTC ...
Preliminary Safety and Efficacy Data from Phase 1 b/2a Trial of RX-5902 in Advanced Triple Negative Breast Cancer. Updated Safety and Efficacy Data on RX-3117 in Advanced Urothelial Cancer. ROCKVILLE, ...
Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/255,901, "Quinoxalinyl Piperazinamide Methods of Use". The allowed patent application covers the use of RX-5902, also known as Supinoxin for the treatment of cancers including triple negative breast cancer either as monotherapy or in combination with other anti-tumor agents such as cytotoxic agents or immune checkpoint inhibitors. The allowed application will extend the patent protection for uses claimed under this patent until 2036.
NEW YORK, NY / ACCESSWIRE / November 7, 2017 / U.S. markets once again reached record highs on Monday on news of merger deals within the tech industry and continued strength in corporate earnings. The ...
The Rockville, Maryland-based company said it had a loss of 4 cents per share. Losses, adjusted for non-recurring gains, came to 15 cents per share. The results topped Wall Street expectations. The average ...